You are here

Article info

Article menu

Download PDFPDF

Perspective
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
Free

Authors

  1. James Raftery, Wessex Institute for Health R&D, Mailpoint 728, Medical School, University of Southampton, Southampton SO16 7PX, UK; raftery{at}soton,.ac.uk
View Full Text

Citation

Raftery J, Clegg A, Jones J, et al
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
British Journal of Ophthalmology 2007;91:1244-1246.

Publication history

  • Accepted March 14, 2007
  • First published April 12, 2007.
Online issue publication 
March 22, 2016

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

2007 BMJ Publishing Group